Name: | Pancuronium |
---|---|
PubChem Compound ID: | 27350 |
Description: | A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than CURARE but has less effect on the circulatory system and on histamine release. |
Molecular formula: | C35H60Br2N2O4 |
Molecular weight: | 732.67 g/mol |
Synonyms: |
Bromure de pancuronium [INN-French]; Piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl)-, dibromide; 1,1'-(3alpha,17beta-Bis(acetyloxy)-5alpha-androstane-2beta,16beta-diyl)bis(1-methylpiperidinium) dibromide; NA 97; Piperidinium, 1,1'-(2-beta,16-beta-(3-alpha,17-beta-dihydroxy-5-alpha-androstanylene))bis(1-methyl-, dibromide, diacetate; 3alpha,17beta-Diacetoxy-2beta,16beta-dipiperidino-5alpha-androstane dimethobromide; Org NA 97; Pancuronium bromide [USAN:BAN:INN:JAN]; Pancuronium bromide (JP15/USAN); D00492.
show more » |
Name: | Pancuronium |
---|---|
Name (isomeric): | DB01337 |
Drug Type: | small molecule |
Description: | A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than CURARE but has less effect on the circulatory system and on histamine release. |
Synonyms: |
Pancuronium dibromide; Bromure de pancuronium [inn-french]; Pancuronium bromide; Bromuro de pancuronio [inn-spanish]
|
Brand: | Mioblock, Pavulon |
Category: | Neuromuscular Nondepolarizing Agents, Nicotinic Antagonists |
CAS number: | 15500-66-0 |
Indication: | Used as a muscle relaxant during anesthesia and surgical procedures. |
---|---|
Pharmacology: |
Pancuronium is a typical non-depolarising curare-mimetic muscle relaxant. It acts as a competitive acetylcholine antagonist on neuromuscular junctions, displacing acetylcholine (hence competitive) from its post-synaptic nicotinic acetylcholine receptors. It is, unlike suxamethonium, a non-depolarising agent, which means, that it causes no spontaneo...
show more » |
Mechanism of Action: | Nondepolarizing neuromuscular blocking agents inhibit neuromuscular transmission by competing with acetylcholine for the cholinergic receptors of the motor end plate, thereby reducing the response of the end plate to acetylcholine. This type of neuromuscular block is usually antagonized by anticholinesterase agents. |
Protein binding: | 77 to 91% |
Biotransformation: | Hepatic. |
Half Life: | 1.5 to 2.7 hours. |
Clearance: | Plasma cl=1.1–1.9 mL/minute/kg |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|